Figure 12.Relationship between DRS and immunotherapy. (A, B) Survival analysis for overall survival and progression-free survival of the two DRS groups in patients with ccRCC who were treated with nivolumab from the RCC-Braun_2020 cohort. (C) Comparison of DRS of different patients with ccRCC in different remission states after immunotherapy in RCC-Braun_2020 cohort. (ns, p > 0.05; *p < 0.05).
